VOLUME 62 2001 NUMBER 4
Commentary
221 The Need for Clinically Relevant Research on
Treatment-Resistant Depression. Michael E. Thase
[PDF]
Brainstorms
225 Why Drugs and Hormones May Interact in Psychiatric
Disorders. Stephen M. Stahl
[PDF]
Original Articles
227 Bupropion Sustained Release for Bereavement: Results of an
Open Trial. Sidney Zisook, Stephen R. Shuchter, Paola
Pedrelli, Jeremy Sable, and Simona C. Deaciuc
[Abstract]
[PDF]
231 Factors Influencing Acute Weight Change in Patients With
Schizophrenia Treated With Olanzapine, Haloperidol, or
Risperidone. Bruce R. Basson, Bruce J. Kinon, Cindy C. Taylor,
Keith A. Szymanski, Julie A. Gilmore, and Gary D. Tollefson
[Abstract]
[PDF]
239 A Randomized Controlled Trial of Risperidone in the
Treatment of Aggression in Hospitalized Adolescents With
Subaverage Cognitive Abilities. Jan K. Buitelaar, Rutger Jan
van der Gaag, Peggy Cohen-Kettenis, and Caroline T. M. Melman
[Abstract]
[PDF]
249 Antidepressant-Induced Mania in Bipolar Patients:
Identification of Risk Factors. Chantal Henry, Frederic
Sorbara, Jerome Lacoste, Claire Gindre, and Marion Leboyer
[Abstract]
[PDF]
256 Effects of Nefazodone on Body Weight: A Pooled Analysis of
Selective Serotonin Reuptake Inhibitor and
Imipramine-Controlled Trials. Norman Sussman, David L.
Ginsberg, and Jessica Bikoff
[Abstract]
[PDF]
261 Health-Related Quality-of-Life Measure Enhances Acute
Treatment Response Prediction in Depressed Inpatients. Jeffrey
M. Pyne, Dale Bullock, Robert M. Kaplan, Thomas L. Smith, J.
Christian Gillin, Shahrokh Golshan, John R. Kelsoe, and D. Keith
Williams
[Abstract]
[PDF]
269 Smoking Habits in Bipolar and Schizophrenic Outpatients in
Southern Israel. Olga Itkin, Boris Nemets, and Haim Einat
[Abstract]
[PDF]
273 Long-Term Olanzapine Therapy in the Treatment of Bipolar I
Disorder: An Open-Label Continuation Phase Study. Todd M.
Sanger, Starr L. Grundy, P. Joseph Gibson, Madhav A. Namjoshi,
Michael G. Greaney, and Mauricio F. Tohen
[Abstract]
[PDF]
282 Optimal Dosing With Risperidone: Updated Recommendations. Richard
Williams
[Abstract]
[PDF]
290 An Open-Label Study of the Treatment Efficacy of
Olanzapine for Tourette's Disorder. Cathy L. Budman, Alex
Gayer, Martin Lesser, Qiuhu Shi, and Ruth D. Bruun
[Abstract]
[PDF]
CME Article 303
304 Use of the Brief Psychiatric Rating Scale to Facilitate
Differential Diagnosis at Acute Inpatient Admission. Derek R.
Hopko, Patricia M. Averill, David Small, Helen Greenlee, and Roy
V. Varner
[Abstract]
[PDF]
Letters to the Editor
295 Cost Savings With Intramuscular Anticholinergics. John
S. Markowitz, Stephen McLeod-Bryant, and Cherry Wyant Jackson
[PDF]
295 Problems With Ensuring a Double Blind. Shailesh Kumar
and Mark Oakley-Browne
[PDF]
- Reply by Raffaella Zanardi, David Rossini, and Alessandro Serretti
296 Low-Dose Olanzapine for Self-Mutilation Behavior in
Patients With Borderline Personality Disorder. David W. Hough
[PDF]
297 Successful Treatment of Nondelusional Body Dysmorphic
Disorder With Olanzapine: A Case Report. Jon E. Grant
[PDF]
298 Olanzapine in the Treatment of Tardive Dyskinesia: A
Report of 2 Cases. Vivek Agarwal and Parvesh Kumar
[PDF]
Book Reviews 300
Information for authors
see January 2001, pages 7577 or our Web site at www.psychiatrist.com/author.htm